GabonTuberculosis profile
Population  2017 2 million
Estimates of TB burden*, 2017 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 2 (1.2–3) 98 (58–150)
Mortality (HIV+TB only) 0.98 (0.61–1.4) 48 (30–71)
Incidence  (includes HIV+TB) 11 (6.9–15) 529 (342–755)
Incidence (HIV+TB only) 2.2 (1.4–3.3) 111 (69–162)
Incidence (MDR/RR-TB)** 0.44 (0.2–0.77) 22 (9.7–38)
Estimated TB incidence by age and sex (thousands)*, 2017
  0-14 years > 14 years Total
Females 0.7 (0.27–1.1) 3.4 (1.3–5.5) 4.1 (1.9–6.3)
Males 0.78 (0.3–1.3) 5.9 (2.3–9.4) 6.6 (3.1–10)
Total 1.5 (0.82–2.1) 9.2 (5.1–13) 11 (6.9–15)
TB case notifications, 2017  
Total cases notified 5 569
Total new and relapse 5 209
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 23%
          - % pulmonary 92%
          - % bacteriologically confirmed among pulmonary 48%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2017 49% (34–75)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2017 0.29 (0.16–0.44)
TB/HIV care in new and relapse TB patients, 2017 Number (%)
Patients with known HIV-status who are HIV-positive 578 48%
          - on antiretroviral therapy 578 100%
Drug-resistant TB care, 2017 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  200
(120–270)
Estimated % of TB cases with MDR/RR-TB 2.5% (1.1–4.3) 14% (10–18)  
% notified tested for rifampicin resistance 11% 40% 772
MDR/RR-TB cases tested for resistance to second-line drugs   17
Laboratory-confirmed cases MDR/RR-TB: 43, XDR-TB: 2
Patients started on treatment **** MDR/RR-TB: 15, XDR-TB:
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2016 48% 5 281
Previously treated cases, excluding relapse, registered in 2016 45% 408
HIV-positive TB cases registered in 2016    
MDR/RR-TB cases started on second-line treatment in 2015 57% 7
XDR-TB cases started on second-line treatment in 2015    
TB preventive treatment, 2017  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2018  
National TB budget (US$ millions) 11
Funding source: 17% domestic, 26% international, 57% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2017
age_sex_graph
____
 
FemalesMalesIncidence

Treatment success rate (%)
tx success graph
   New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__
Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2019-09-19 Data: www.who.int/tb/data